Answers are grounded in this paper and cite their sources.
Recurrence of primary sclerosing cholangitis (PSC) after liver transplantation has been a subject of debate for nearly two decades.1-5 The dispute was put to rest after the common observation of a higher incidence of otherwise unexplained bile duct strictures in the hepatic allografts given to PSC vs. non-PSC patients.4, 6, 7 The first case report suggesting disease recurrence was published in 19881 followed by an increasing number of scientific articles with convincing radiologic and histopathologic evidence of disease recurrence.2-10 PSC, primary sclerosing cholangitis. The gold standard criteria diagnostic of PSC in the native liver was adopted to define disease recurrence in the allograft.11-13 However, the possible coexistence of nonspecific bile duct injuries and strictures due to allograft reperfusion injury, ischemia, rejection, and recurrent biliary sepsis due to a technically flawed biliary reconstruction challenged the unequivocal diagnosis of PSC recurrence.4, 7, 9, 14, 15 Accordingly, a list of exclusion criteria including ischemic cholangiopathy, anastomotic biliary strictures, non–heart beating donors, long cold ischemia time, ABO incompatibility, and chronic rejection were integrated in the study design to define with certainty the true risk of disease recurrence. The accepted radiologic features are intrahepatic and/or extrahepatic nonanastomotic biliary strictures, or, more specifically, the development of mural irregularities and diverticulum-like outpouchings.8 The lack of sludge and biliary casts favors the diagnosis of recurrent disease over ischemic cholangiopathy. Endoscopic retrograde cholangiopancreatography and, more recently, magnetic resonance cholangiography have been the standard radiologic tools for diagnosis of native PSC.11-13 Because of the Roux-en-Y hepaticojejunostomy, percutaneous transhepatic cholangiography has been the only technically feasible and definitive imaging tool for diagnosis of recurrence in the allograft. Brandsaeter and his colleagues have introduced, in this issue, the systematic use of magnetic resonance cholangiography as a reliable noninvasive radiologic test for imaging of central and peripheral biliary strictures with diagnosis of PSC recurrence.7 However, magnetic resonance cholangiography has yet to be validated as a useful tool to accurately assess the degree of strictures with identification of the mural irregularities and diverticulum-like outpouchings specific of disease recurrence.8 Histologic findings suggestive of disease recurrence have been defined by fibrosing cholangitis and fibro-obliterative duct lesions.3 However, similar changes can be seen with other causes of biliary strictures with no discriminating features. Such an overlap particularly with chronic rejection questioned the validity of hepatic histopathology as a sole definition of PSC recurrence.7, 9, 14, 16 The histopathologic similarity between chronic rejection and PSC recurrence arises because of the development of ischemic periductal lamellar fibrosis induced by the obliterative arteriopathy. However, chronic rejection rarely induces radiologic strictures and is associated with a relatively unfavorable clinical outcome.14 Ideally, a distinctive diagnosis of PSC recurrence mandates documentation of the characteristic cholangiographic findings combined with compatible histopathologic changes after exclusion of other causes of biliary strictures. Recurrence of PSC in the liver allograft has been reported at different rates by different centers with a cumulative risk ranging from 0 to 60%.4, 5, 7, 17-19 The significant disparity in the reported incidence of disease recurrence could be related to variation in duration of follow-up, study designs, and adopted diagnostic criteria. Other observed differences were the immunosuppressive protocols and weight of potential predisposing factors among the studied population. It is also imperative to emphasize the retrospective nature of most studies with cholangiograms and liver biopsies being performed only when clinically indicated. The report7 published herein is an example of the commonly adopted study design with clinically matched controls and statistical methods utilizing univariate and multivariate regression analyses. Of great interest are the reported isolated instances of biliary strictures, characteristic of PSC, among the non-PSC control group. These findings may represent a de novo PSC in the allograft or are examples of the overlap syndrome with a pretransplant nonspecified autoimmune liver disease.9, 20-23 Risk factors and pathogenesis of PSC recurrence in the liver allograft have been the primary focus of few European and North American transplant centers.4-7, 15, 19 The examined factors were patient age, gender, presence of native colon, coexistence of inflammatory bowel disease, history of colorectal cancer, pre-transplant severity of PSC disease, operative time and blood loss, number of transplants, cold ischemia time, ABO mismatched grafts, cytomegaloviral disease, rejection, severity of inflammatory bowel disease, and choice of calcineurin inhibitors. While few studies identified steroid-resistant rejection and subsequent use of monoclonal or polyclonal antibodies as significant risk factors for disease recurrence,7, 14, 24 the Birmingham, UK, group was able to define different predictors including male gender, intact colon, inflammatory bowel disease, cytomegaloviral disease, number of transplants, withdrawal of steroids, operative blood loss, and serum albumin level, with male sex and intact colon being the only significant predictors with multivariate analysis.15, 19 Interestingly, the allograft human leukocyte antigen haplotypes and disparity with the recipient were not predictive or protective of disease recurrence.7, 14 Also, the type of calcineurin inhibitor used for maintenance immunosuppression and length of corticosteroid use were not significant risk factors in all but 2 studies.14, 24 The pathogenesis of PSC could hypothetically be linked to autoimmunity, cross-sensitization between biliary and colonic antigens due to common epithelial epitopes, bacterial or viral infections, or leak of bacterial toxins from the inflamed colon with possible familial or genetic predisposition.14, 15, 25, 26 The leaking theory is supported by our recent observation of the development of pericholangitis among short bowel syndrome patients and intestinal allograft recipients at the time of bacterial overgrowth, preservation injury, rejection, or enteritis (unpublished data). Of great interest, also, is our published observation of worsening inflammatory bowel disease in the native colon after liver transplantation and concomitant use of immunosuppression.27 The enigma of the enterohepatic link has been recently explained by the proven ability of certain subpopulations of the mucosal lymphocytes to home both the liver and the gut because of overlapping addressins (Mad CAM-1).28 The susceptibility of the transplanted liver to de novo or recurrent PSC as well as the natural history of the allograft disease process may be influenced by the used immunosuppression and human leukocyte antigen disparity between graft and host. The reported lack of correlation between the allograft human leukocyte antigen and disease recurrence7, 14 may emphasize the role of the recipient human leukocyte antigen–specific haplotype as a genetic predisposing factor rather than an antigen for immune recognition. The correlation commonly observed between destructive alloimmunity and PSC recurrence could be due to an increase in the number of the autoimmune biliary epitopes with further ductal damage. An alternative explanation is a hyperresponsive immune system that predisposes to both rejection and PSC recurrence. The suspected role of cytomegaloviral infection could be attributed to modulation of the immune repertoire and subsequent disease progression. Furthermore, additional unknown host or graft factors could also be incriminated, since disease recurrence does not invariably occur in a regraft.15, 19 The slow natural progression of native PSC and the uncertainty of unequivocal diagnosis in the allograft questioned the significant impact of disease recurrence on survival after transplantation. However, the cumulative increase in the number of long-term survivors allowed recent studies to declare some graft failure, retransplantation, and even patient death due to disease recurrence.5, 7, 15, 19 Nonetheless, the overall cumulative impact on the allograft half-life and patient survival by comparing recipients with and without PSC recurrence has yet to be fully defined. In summary, recurrence of PSC in the liver allograft, despite lack of unequivocal evidences, is a well-recognized clinical, radiologic, and histopathologic entity. The recent availability and future technical evolution of the magnetic resonance cholangiography as a noninvasive imaging technique should allow systematic examination of these unique recipients with full documentation of disease recurrence in both symptomatic and asymptomatic patients. Revelation of the unequivocal risk factors may guide dissection of the true pathogenesis of the primary as well as the recurrent disease. Based upon current published and unpublished data (University of Pittsburgh), long-term survivors with recurrent disease experience significant morbid events with negative impact on graft survival and patient quality of life. However, large-scale longitudinal multicenter studies or meta-analyses of long-term survivors are required to determine the cumulative effect of disease recurrence on survival outcome particularly the half-life of the allografted liver.
No takes yet. Share an insight, caveat, or question.
Abu‐Elmagd et al. (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: